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Coronary Sinus Reducer Stent for
the Treatment of Chronic Refractory Angina Pectoris
A Prospective, Open-Label, Multicenter, Safety Feasibility First-in-Man Study
Shmuel Banai, MD,* Shmuel Ben Muvhar,† Keyur H. Parikh, MD,‡ Aharon Medina, MD,§
Horst Sievert, MD, Ashok Seth, MD,¶ Jonathan Tsehori, MD,* Yoav Paz, MD,*
Ami Sheinfeld, MD,# Gad Keren, MD*
Tel Aviv, Or Yehuda, Jerusalem, and Ramat Gan, Israel; Ahmedabad and New Delhi, India;
and Frankfurt, Germany
Objectives This study sought to evaluate the safety of the Coronary Sinus Reducer (Neovasc Medical, Inc., Or Yehuda, Israel)
as a potential alternate therapy for patients with refractory angina who are not candidates for conventional re-
vascularization procedures.
Background Increased coronary sinus (CS) pressure can reduce myocardial ischemia by redistribution of blood from nonischemic
to ischemic territories. The Coronary Sinus Reducer is a percutaneous implantable device designed to establish
CS narrowing and to elevate CS pressure. In preclinical experiments, implantation of the Reducer was safe and
was associated with improved ischemic parameters. In the present study, the safety and feasibility of the Coronary
Sinus Reducer was evaluated in patients with refractory angina who were not candidates for revascularization.
Methods Fifteen coronary artery disease patients with severe angina and reversible ischemia were electively treated with
the Reducer. Clinical evaluation, dobutamine echocardiography, thallium single-photon emission computed to-
mography, and administration of an angina questionnaire were performed before and 6 months after implanta-
tion. Cardiac computed tomography was performed 2 days and 6 months after implantation.
Results All procedures were completed successfully. No procedure-related adverse events occurred during the periproce-
dural and the follow-up periods. Angina score improved in 12 of 14 patients. Average Canadian Cardiovascular
Society score was 3.07 at baseline and 1.64 at follow-up (n  14, p  0.0001). Stress-induced ST-segment de-
pression was reduced in 6 of 9 patients and was eliminated in 2 of these 6 (p  0.047). The extent and severity
of myocardial ischemia by dobutamine echocardiography and by thallium single-photon emission computed to-
mography was reduced (p  0.004 [n  13] and p  0.042 [n  10], respectively).
Conclusions Implantation of the Coronary Sinus Reducer is feasible and safe. These findings, along with the clinical improve-
ment observed, support further evaluation of the Reducer as an alternative treatment for patients with chronic
refractory angina who are not candidates for coronary revascularization. (J Am Coll Cardiol 2007;49:1783–9)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.061c
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the increasing number of coronary revascularization proce-
ures along with improved drug and device therapies has
reatly increased the life expectancy of patients with coro-
ary artery disease (CAD). However, there are still a
rom the *Cardiology Department, Tel Aviv Medical Center, Tel Aviv, Israel;
Neovasc Medical, Inc., Or Yehuda, Israel; ‡The Heart Care Clinic/SAL Hospital,
hmedabad, India; §Bikur Cholim Hospital, Jerusalem, Israel; Cardio Vascular
enter Frankfurt, Sankt Katharinen, Frankfurt, Germany; ¶Max Devki Devi Heart
nd Vascular Institute, New Delhi, India; and the #Sheba Medical Center, Ramat
an, Israel. The research and development of the Coronary Sinus Reducer stent were
one by Neovasc Medical, Inc. Drs. Banai and Keren are active consultants and
hmuel Ben Muvhar is the Chief Executive Officer of Neovasc Medical, Inc.i
Manuscript received September 22, 2006; revised manuscript received January 2,
007, accepted January 2, 2007.onsiderable number of patients who remain severely dis-
bled by chronic refractory angina pectoris. This group of
atients is rapidly growing because of the improvement of
ardiovascular care provided. It is estimated that 5% to 10%
f patients with angina pectoris have refractory angina.
hose in this group of no-option patients often have severe
iffuse CAD and are not candidates for further revascular-
zation by coronary artery bypass graft (CABG) surgery or
ercutaneous coronary intervention (PCI) (1,2). The esti-
ated 1- and 3-year mortality rates for these patients are 1%
o 5%, and up to 24%, respectively (2–7).
A considerable number of therapeutic strategies for treat-ng severe chronic angina have been investigated (8,9). All
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none of these approaches has be-
come a widely used therapy. In
the setting of obstructive CAD,
increased coronary sinus (CS)
pressure can lead to redistribu-
tion of collateral blood flow from
nonischemic into ischemic terri-
tories of the myocardium. Such
redistribution of arterial blood
significantly reduces myocardial
ischemic damage and infarct size
(10–15).
The Coronary Sinus Reducer
(Neovasc Medical, Inc., Or Ye-
huda, Israel) is a stainless steel
balloon-expandable stent spe-
ially designed to establish a narrowing of the CS, which is
he final pathway of the cardiac venous drainage, and to
ncrease coronary venous pressure. The Reducer is im-
lanted by a percutaneous transvenous approach. In a set of
reclinical experiments, we have shown that implantation
he Coronary Sinus Reducer is feasible and safe. In ischemic
earts, implantation of the Reducer was associated with re-
uced mortality and improved ischemic parameters. Our hy-
othesis is that in patients with CAD and refractory angina
ho are not candidates for conventional revascularization
rocedures, elevating CS pressure with the Reducer might
nhance perfusion to ischemic territories of the myocardium
nd improve their symptoms. As a first step in the evaluation
f the Coronary Sinus Reducer as a potential alternative
herapy for patients with refractory angina who are not candi-
ates for revascularization, a first-in-man study was conducted.
ethods
his was a multicenter, nonrandomized, open-label pro-
pective study that evaluated the safety and feasibility of the
oronary Sinus Reducer. All patients received the intended
herapy. The study was conducted at 3 sites in Germany and
n India.
atients. Patients were eligible for inclusion in the study if
hey had a history of CAD with refractory angina (Cana-
ian Cardiovascular Society [CCS] class II to IV) despite
ptimal medical therapy, objective evidence of reversible
yocardial ischemia, and ejection fraction 30%. All pa-
ients were considered unacceptable candidates for PCI or
ABG. All were treated electively with implantation of the
oronary Sinus Reducer.
NCLUSION CRITERIA.
. Symptomatic CAD with refractory angina defined as
CCS class II to IV, despite medical therapy.
. Patients with CAD who were either not amenable to or
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CCS  Canadian
Cardiovascular Society
CS  coronary sinus
CT  computed
tomography
PCI  percutaneous
coronary intervention
SPECT  single-photon
emission computed
tomographywere at high risk for CABG or PCI.. Reversible myocardial ischemia, determined by perfu-
sion scan and/or by dobutamine echocardiography.
. Left ventricular ejection fraction 30%.
XCLUSION CRITERIA.
. Recent (within 3 months) myocardial infarction.
. Recent (within 7 months) PCI or CABG.
. Severe arrhythmias, including chronic atrial fibrillation.
. Decompensated heart failure.
. Severe valvular heart disease.
. Pacemaker or other CS electrode.
. Mean right atrial pressure 15 mm Hg.
. Patients who had undergone tricuspid valve replacement
or repair.
he device. The Reducer is a stainless steel balloon-
xpandable stent designed to establish narrowing of the
S (Fig. 1). The diameter at its mid portion is 3 mm, and
t can reach a diameter of 7.0 to 13.0 mm at both ends
sing inflation pressure of 2 to 4 bars. The Reducer is
ntroduced into the CS through the right internal jugular
ein.
In case it is necessary to remove the narrowing from the
S, balloon inflation to a pressure of 8 bars will completely
pen the Reducer, which will then attain a tubular shape.
tudy end points. PRIMARY END POINT: SAFETY. The pri-
ary end point in this study was the absence of any major
dverse cardiac events related to the procedure during 6
onths of follow-up. An adverse event was defined as
eath, myocardial infarction, perforation of the CS, CS
cclusion, or need for urgent dilatation of the Reducer.
ECONDARY END POINT: TECHNICAL SUCCESS. The sec-
ndary end point was successful delivery and deployment of
he Reducer in the CS, as assessed by angiogram and/or by
omputed tomographic (CT) angiography.
ollow-up. Each patient underwent a full clinical evalua-
ion, stress test, radionuclide perfusion study with single-
hoton emission computed tomography (SPECT), and/or
Figure 1 Coronary Sinus Reducer Stent:
A Stainless Steel Balloon-Expandable Stent
(Left) The Reducer stent on the inflated
designated balloon. (Right) The Reducer stent.
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May 1, 2007:1783–9 Coronary Sinus Reducer Stent for Refractory Anginaobutamine echocardiography at baseline (before implanta-
ion of the Reducer) and 6 months later. Dobutamine
chocardiography and thallium SPECT studies were ana-
yzed by core laboratories.
OBUTAMINE ECHOCARDIOGRAPHY. An 18-segment
uantitative analysis was used. The wall motion of each
egment was graded according to a score (0  not scored,
 normal, 2  hypokinetic, 3  akinetic, 4  dyskinetic,
 aneurysmatic). The summed scores of myocardial
ontractility during peak dobutamine infusion at baseline
nd after 6 months were compared. A medically significant
hange was defined as a change of 1 score or more in at least
segments.
YOCARDIAL PERFUSION IMAGING. A 20-segment semi-
uantitative visual analysis and an automated quantitative
nalysis were used. A qualitative comparison between stress
nd rest redistribution images at baseline and at 6-month
ollow-up was made by the calculation of a defect extent
core. The score was derived from the number of abnormal
egments among those evaluated. A medically significant
hange was defined as a difference of at least 4 points in the
otal score.
ARDIAC CT ANGIOGRAPHY. The CT angiographies at 1 to
days of Reducer implantation and at 6 months were
ompared to evaluate the exact placement and patency of
he Reducers.
UALITY OF LIFE AND ANGINA CLASS. The Seattle Angina
uestionnaire for assessing quality of life and angina class
as completed at baseline and at 3 and 6 months of
ollow-up.
EDUCER STENT IMPLANTATION PROCEDURE. Treatment
ith aspirin 100 mg/day and clopidogrel 75 mg/day was
tarted 1 week before implantation. Under fluoroscopic
uidance, a preshaped guiding sheath was introduced into
he CS through a right internal jugular vein. After CS
ressure was recorded, angiography was performed. The
imensions of the proximal segment of the CS were
easured using quantitative coronary angiography. The
ptimal site for implantation was chosen according to the
essel diameters and to avoid side branch bifurcation. The
educer, crimped on a balloon, was then inserted over the
ire into the CS, positioned at the desired site, and
mplanted by inflating the balloon. Postimplantation an-
iography was performed to ensure appropriate implanta-
ion, patency, and appropriate reduction of the lumen’s
iameter, and to ensure lack of migration of the Reducer,
hrombosis within the Reducer or the CS, and perforation
r dissection of the CS (Fig. 2).
tatistical analysis. The baseline and follow-up measure-
ents were compared using the one-sided Wilcoxon
igned rank test; p  0.05 was considered statistically
ignificant. sesults
atients. From October 2004 to July 2005, a single Reducer
as implanted in the CS of 15 patients at 3 medical centers.
ll had proven CAD, evidence of reversible myocardial isch-
mia by dobutamine echocardiography, and/or thallium
PECT, and all suffered from refractory angina. The clinical
haracteristics of the patients are presented in Table 1.
One patient who was included in the safety/feasibility
nalysis was excluded from the quality of life/angina score
nalysis as well as from the stress and perfusion test analyses.
his patient continued to suffer from severe angina after
mplantation of the Reducer. His cardiac CT angiography
Figure 2 Implantation of the Coronary
Sinus Reducer Stent in Human Coronary Sinus
(A) Contrast-filled inflated balloon at the time of implantation of the Reducer
stent in human coronary sinus. (B) Retrograde angiography of the coronary
sinus after implantation of the Reducer.howed a diseased saphenous vein graft that was missed
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Coronary Sinus Reducer Stent for Refractory Angina May 1, 2007:1783–9uring his baseline coronary angiogram. The obstructive
aphenous vein graft lesion was treated with a stent, and the
atient’s symptoms improved significantly.
rimary and secondary end points. All implantation pro-
edures were completed successfully. All patients were
ischarged from the hospital 1 to 2 days later without
linical complications. No major adverse cardiac events had
ccurred during the periprocedural period or during the
ollow up period of 10 to 12 months (mean follow-up 11 
.03 months).
dditional evaluation. CT ANGIOGRAPHY. In 12 patients,
T angiography was performed. All Reducers were patent,
ell positioned, and located at the exact site of deployment
ith no evidence of migration. The mean diameters of the
educers as measured in the postimplantation multislice
T were: proximal 11 2 mm, distal 7.2 1 mm, and mid
.0  0.2 mm (Fig. 3).
linical Characteristics of the Patients
Table 1 Clinical Characteristics of the Patients
Characteristic n
Male 12
Female 3
Age (yrs) 50–80 (mean 65)
S/P myocardial infarction 4
S/P percutaneous coronary intervention 6
S/P coronary artery bypass graft 3
Hypertension 10
Hyperlipidemia 5
Diabetes 1
Angina class
CCS 2 1
CCS 3 12
CCS 4 2
Number of diseased vessels
1 3
2 6
3 6
CS  Canadian Cardiovascular Society; S/P  status post.
Figure 3 Cardiac Computed Tomographic Angiography of Huma
(A) Three-dimensional reconstruction of the posterior aspect of the heart. The Reduce
clearly seen. (B, C) Longitudinal section of the coronary sinus. The proximal and distaNGINA SCORE. Angina score improved significantly 6
onths after implantation. The CCS class was lower after 6
onths in 12 of the 14 patients and remained constant in 2.
he average CCS class for the 14 patients was 3.07 at
aseline and 1.64 at follow-up (p 0.0001). The individual
nd per-the-group changes in CCS class are outlined in
igures 4A and 4B. Most patients reported improvement in
uality of life and reduction in anginal symptoms only
everal weeks after implantation of the Reducer, and not
mmediately after implantation.
T-SEGMENT DEPRESSION DURING EXERCISE STRESS
EST. Of the 11 patients in whom electrocardiographic
racings at baseline and at the 6-month stress test were of
ood technical quality, transient ST-segment depression
as documented during the baseline exercise stress test in 9.
t 6-month follow-up, ST-segment depression was lower
n 6 of these 9 patients, and was no longer present in 2 of the
. One patient had a higher ST-segment depression at 6
onths. The average ST-segment depression for the 9
atients was 2.00 mm at a mean heart rate of 117 beats/min
t baseline and 1.22 mm at a mean heart rate of 124
eats/min at follow-up (p  0.047) (Fig. 5). In 9 of the 11
atients, exercise duration and peak heart rate increased at
he 6-month follow-up stress test compared with baseline.
or the whole group, the average double product and
xercise duration were unchanged 6 months after implan-
ation compared with baseline (18,675 at baseline vs. 20,365
t 6 months [p  0.18] and 7.08 at baseline vs. 6.79 at 6
onths [p  0.59], respectively).
OBUTAMINE ECHOCARDIOGRAPHY. In 13 of the 14 pa-
ients, dobutamine echocardiography data were of good
echnical quality. In 8 of these 13 patients there was a
edically significant improvement (a change of 1 score or
ore in at least 2 segments) when the stress images at
aseline and 6 months were compared. The average score of
ll 18 segments was lower at 6 months (baseline 25.08, 6
arts After Implantation of the Coronary Sinus Reducer Stent
implanted at the proximal segment of the coronary sinus is
eters of the Reducer perfectly match the funnel-shaped coronary sinus.n He
r stent
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May 1, 2007:1783–9 Coronary Sinus Reducer Stent for Refractory Anginaonths 1.08, difference 4.00; p  0.004) (Fig. 6). Of the
emaining 5 patients, 3 had a higher total score at 6 months
han at baseline and 2 had a lower score; the differences were
elatively small, and all 5 had low baseline values.
HALLIUM SPECT PERFUSION STUDIES. In 10 patients
PECT images were of good technical quality at baseline
nd 6 months. In 4 of the 10 patients there was a medically
ignificant reduction in the extent and/or severity of myo-
ardial ischemia as measured by the total score. Among the
emaining 6 patients, the SPECT images were unchanged
n 5 and worsened in 1 patient at 6 months. The average
core for the group was 12.6 at baseline and 9.6 at 6 months,
 0.042 (n  10).
iscussion
his is the first human experience with the implantation of
oronary Sinus Reducer. The absence of adverse events for
p to 12 months of follow-up suggests that the implantation
f the Reducer is feasible and safe. The present safety/
Figure 4 Angina Score (CCS) Before and 3
and 6 Months After Implantation of the Reducer
(A) Individual patients’ angina scores are presented at baseline and at 3 and
6 months after implantation. The Canadian Cardiovascular Society (CCS) class
improved in 12 of the 14 patients 6 months after implantation and remained
constant for 2 patients (p  0.0001, n  14). (B) The average angina score
for the group, before implantation of the Reducer and 3 and 6 months later
(n  14).easibility study is the first step in the clinical evaluation ofhe Coronary Sinus Reducer as a possible treatment for
atients with refractory angina.
The majority of patients suffering from CAD can be
dequately treated by drug therapy and by revascularization.
mproved drug therapy and the refinement of revasculariza-
ion techniques have greatly increased the life expectancy
nd improved quality of life for these patients in the last few
ecades. Nevertheless, despite an increasing number of
oronary interventions over recent years, there are still a
onsiderable number of patients suffering from chronic
efractory angina pectoris. The percentage of these no-
ption patients is not known exactly, but has been suggested
o be 30 per million inhabitants per year; other estimates are
.5% to 5% of coronary angiography procedures (1,8). The
roup of no-option patients includes those who have angina
espite optimal medical therapy. These patients may not have
een offered PCI or CABG because of the severe diffuse nature
f their coronary disease, or these patients may continue to
xperience severe angina after CABG and PCI.
A considerable number of therapeutic strategies for treat-
ng refractory angina have been investigated, none of which
as become an accepted and widely used tool in today’s
linical practice. Elevated coronary venous pressure achieved
y narrowing of the CS as a therapeutic approach for
atients with disabling angina was first described and used
y Beck and Leighninger in 1955 (16,17).
Elevating CS pressure using intermittent CS occlusion
nd pressure-controlled intermittent CS occlusion have
een described to be effective in salvaging ischemic myocar-
ium in several experimental models of coronary artery
Figure 5 Exercise-Induced ST-Segment
Depression Before and 6 Months After Implantation
Transient ST-segment depression was present during the baseline stress test
in 9 patients. At 6-month follow-up, ST-segment depression was lower in 6
patients and was no longer present in 2 of the 6. For ST-segment depression,
the average for the 9 patients was 2.00 mm at baseline and 1.22 mm at
follow-up (p  0.047).
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Coronary Sinus Reducer Stent for Refractory Angina May 1, 2007:1783–9cclusion (18,19); however, the modes of action of these
nterventions remain speculative. The CS pressure elevation
nhances coronary collateral flow and reduces subendocar-
ial ischemia, with a positive correlation between the
levated CS pressure and the changes in collateral blood
ow from nonischemic to ischemic territories of the myo-
ardium (11).
Clinical application of CS interventions during the
arly reperfusion period has shown improvement in
egional myocardial function and salvaging of ischemic
yocardium, especially by limiting the infarct from its
order (13,14,20 –22).
Few pathophysiological mechanisms are proposed to
xplain the anti-ischemic effects of elevated CS pressure:
rst, the opening of pre-existing collateral vessels between
ormally perfused and ischemic segments of the myocar-
ium; and second, reversal of the endocardial/epicardial
lood flow ratio in favor of the endocardium with an
ncrease in endocardial blood flow (10). In the long run, the
otential for formation of new blood vessels also has been
uggested.
Significant stenosis of an epicardial coronary artery is
Figure 6 Stress Dobutamine Echocardiography Results at
Baseline and 6 Months After Reducer Implantation
The score of all 18 segments of stress dobutamine echocardiography images
were summed and compared at baseline (0 months) and at 6 months after
Reducer implantation. The individual patients’ data are presented. For the
group (n  13), the mean score was lower at 6 months (average at baseline
25.08, average at 6 months 21.08, difference  4.00; p  0.004).ssociated with decreased myocardial perfusion and acti- oation of compensatory mechanisms to overcome this
imitation. Distal vessels dilate, and pre-existing collat-
ral connections are opened and develop over time into
ignificant vessels that transmit blood from normally
erfused territories to ischemic regions. New coronary
ollaterals develop over time as well. Previous studies
ith an increase in CS pressure have shown clearly that
he coronary collateral circulation is enhanced in a
ignificant way by this intervention.
Furthermore, the subendocardium is more vulnerable to
schemic damage than the midmyocardium or subepicar-
ium. Epicardial coronary stenoses are associated with
eduction in the subendocardial-to-subepicardial flow ratio.
his mechanism, which has been demonstrated in multiple
xperiments, is explained by the high intramyocardial forces
cting on vessels in the subendocardium. This high in-
ramyocardial force does not enable the vasodilatory re-
ponse of the vascular system to fully compensate for the
ecrease in coronary perfusion caused by the stenosis. The
oronary Sinus Reducer, by increasing backpressure into
he precapillary arteriolar system, will facilitate dilatation
f the constricted subendocardial capillaries. Any change
n the diameter of these vessels will be more pronounced
han the changes taking place in the already-dilated vessels
n the epicardial territory, thereby facilitating the directional
hanges in flow toward the subendocardial segments (10–
2,14). Improved capillary perfusion in the subendocardium
f the ischemic territory will improve contractility and
ncreased oxygen consumption (15).
Our hypothesis is that in the setting of obstructive CAD,
y increasing CS pressure, perfusion of the myocardium in
schemic areas will be enhanced and consequently hemody-
amic parameters and symptoms of angina will improve. To
est the validity of our hypothesis we have conducted a set of
reclinical experiments followed by this first-in-man study.
Preclinical experiments have shown that implantation of
he Coronary Sinus Reducer in pig hearts was feasible and
afe and carried no short- or long-term complications. No
hort- or long-term complications were observed during
ollow-up of up to 1 year. The mean pressure gradient
easured across the reducers was 3.71  1.75 mm Hg
mmediately after implantation and 2.83  1.47 mm Hg 6
onths later. In a pig model of reversible myocardial
schemia, implantation of the Reducer was associated with
educed mortality and improved ischemic parameters.
The present study has shown that the use of this new
echnique to establish a narrowing of the CS is feasible and
afe. Whether or not the reduction in CS diameter and the
ncreased CS pressure will subsequently improve collateral
lood flow into ischemic territories of the myocardium,
educe ischemia, and improve symptoms of angina is still to
e proven in a larger clinical study designed and powered to
rove efficacy.
Refractory angina is a chronic condition with little change
ver time. In the present study, 6 months after implantation
f the Coronary Sinus Reducer, angina score improved in 12
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May 1, 2007:1783–9 Coronary Sinus Reducer Stent for Refractory Anginaf 14 patients, stress-induced ST-segment depression was
educed in 6 of 9 patients and was eliminated in 2 of the 6,
he severity of dobutamine-induced myocardial ischemia
as significantly reduced in 8 of 13 patients, and in 4 of 10
atients the extent and severity of myocardial ischemia was
educed by thallium SPECT. Although not designed and
ot powered to prove efficacy, the improvement in subjec-
ive and objective ischemic parameters observed might
eflect the potential efficacy of this device in the treatment of
efractory angina. It should be emphasized that until a
andomized placebo-controlled trial is conducted, it can not
e ruled out that the subjective improvement observed is not
ttributed to a placebo effect. Such a placebo effect has been
eported in many refractory angina trials.
onclusions
n this open-label, multicenter, nonrandomized, prospective
tudy, the use of percutaneous transvenous implantation of
he Coronary Sinus Reducer in patients with refractory
ngina was found to be safe and feasible. These findings,
long with the clinical improvement observed, support
urther evaluation of the Coronary Sinus Reducer in a
andomized placebo-controlled trial, as an alternative tool
or treating patients with refractory angina who are not
andidates for or are at high risk for revascularization.
eprint requests and correspondence: Dr. Shmuel Banai, Inter-
entional Cardiology, Tel Aviv Medical Center, 6 Weizman
treet, Tel Aviv, Israel. E-mail: banais@netvision.net.il.
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